Targeting IL-6 in the Treatment of Uveitic Macular Edema - Takeaways - MDSpire

Targeting IL-6 in the Treatment of Uveitic Macular Edema

  • By

  • Rahul Khurana, MD

  • Michael A. Singer, MD

  • January 1, 2026

  • 5 min

Share

  • 1

    Uveitic macular edema is a leading cause of vision loss in uveitis patients, with nearly 50% experiencing persistent edema despite treatment.

  • 2

    Vamikibart, an IL-6 targeting molecule, showed promising results in phase 3 trials, improving visual acuity by about 10 letters compared to sham.

  • 3

    Both doses of vamikibart demonstrated safety with low rates of intraocular inflammation, cataract, and intraocular pressure complications.

  • 4

    The pharmacokinetic data indicated that IL-6 suppression with vamikibart lasts up to 6 months, suggesting potential durability in treatment.

  • 5

    The ongoing analysis of full-year data will help determine the injection frequency needed for effective management of uveitic macular edema.

Original Source(s)

Targeting IL-6 in the Treatment of Uveitic Macular Edema

  • by Rahul Khurana, MD, Michael A. Singer, MD

  • January 1, 2026

Related Content

AI Falls Short on Differential Dx

New PrIME-LLM benchmark shows strong diagnostic accuracy but persistent gaps in clinical reasoning across 21 large language models

The Art of Ophthalmology 2026

Showcasing artwork and images from across the spectrum of ophthalmology

Imaging Leukocyte Dynamics in Retinal Disease

The movement of immune cells through the retinal vasculature has long been inferred from laboratory models. Now, advances in imaging are allowing clinicians to observe these processes directly. At the 2026 meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Denver, Richard B. Rosen, MD, ScD(hon), FACS, FASRS, FARVO, described early clinical work using adaptive optics scanning laser ophthalmoscopy (AOSLO) to visualize leukocyte trafficking in vivo.